Literature DB >> 16669871

Ovarian epithelial tumors of low malignant potential: are they precursors of ovarian carcinoma?

Manabu Fukumoto1, Kentaro Nakayama.   

Abstract

Ovarian tumors of low malignant potential (LMP) are intermediate between benign adenoma and frank ovarian carcinoma, and are characterized by the absence of destructive stromal invasion, or microinvasion. If LMP did not develop into invasive carcinoma, then a minimally invasive simple treatment could be chosen. However, histological diagnosis cannot completely predict the prognosis of patients with ovarian tumors. It was found that mucinous LMP is most frequent in Japan, whereas serous LMP is the most common in Western countries. Mucinous LMP with loss of heterozygosity (LOH) at chromosomes 5q14-21 and 17q11.2, and serous LMP were suggested to be precursor lesions of ovarian carcinomas. Follow-up study revealed that patients with mucinous LMP who had LOH at 19q12 and/or Xq11-12 were at the greatest risk of progression. It is concluded that molecular genetic analysis such as LOH study could predict prognosis and aid in treatment decision-making. The present review describes molecular genetic changes of LMP and presents problems on LMP that remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16669871     DOI: 10.1111/j.1440-1827.2006.01960.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  11 in total

1.  A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation.

Authors:  J Chien; K Narita; R Rattan; S Giri; R Shridhar; J Staub; D Beleford; J Lai; L R Roberts; J Molina; S H Kaufmann; G C Prendergast; V Shridhar
Journal:  Oncogene       Date:  2008-09-22       Impact factor: 9.867

2.  Identification of novel epithelial ovarian cancer biomarkers by cross-laboratory microarray analysis.

Authors:  Xuefeng Jiang; Tao Zhu; Jie Yang; Shuang Li; Shuangmei Ye; Shujie Liao; Li Meng; Yunping Lu; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-06-17

Review 3.  Origin of ovarian cancer: molecular profiling.

Authors:  Dilip Kumar Dutta; Indranil Dutta
Journal:  J Obstet Gynaecol India       Date:  2013-06-21

4.  Ovarian cancer risk factors in African-American and white women.

Authors:  Patricia G Moorman; Rachel T Palmieri; Lucy Akushevich; Andrew Berchuck; Joellen M Schildkraut
Journal:  Am J Epidemiol       Date:  2009-07-15       Impact factor: 4.897

Review 5.  Genomic analysis of epithelial ovarian cancer.

Authors:  John Farley; Laurent L Ozbun; Michael J Birrer
Journal:  Cell Res       Date:  2008-05       Impact factor: 25.617

6.  Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

Authors:  Michael S Anglesio; Jeremy M Arnold; Joshy George; Anna V Tinker; Richard Tothill; Nic Waddell; Lisa Simms; Bianca Locandro; Sian Fereday; Nadia Traficante; Peter Russell; Raghwa Sharma; Michael J Birrer; Anna deFazio; Georgia Chenevix-Trench; David D L Bowtell
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

Review 7.  Ovarian cancer: genomic analysis.

Authors:  W Wei; D Dizon; V Vathipadiekal; M J Birrer
Journal:  Ann Oncol       Date:  2013-12       Impact factor: 32.976

8.  Increased expression of PITX2 transcription factor contributes to ovarian cancer progression.

Authors:  Frederic K C Fung; David W Chan; Vincent W S Liu; Thomas H Y Leung; Annie N Y Cheung; Hextan Y S Ngan
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

9.  Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer.

Authors:  Romulo M Brena; Carl Morrison; Sandya Liyanarachchi; David Jarjoura; Ramana V Davuluri; Gregory A Otterson; David Reisman; Selina Glaros; Laura J Rush; Christoph Plass
Journal:  PLoS Med       Date:  2007-03-27       Impact factor: 11.069

10.  Oncogenic role of mortalin contributes to ovarian tumorigenesis by activating the MAPK-ERK pathway.

Authors:  Yingying Hu; Ling Yang; Yujie Yang; Yanyan Han; Yongbo Wang; Wen Liu; Ji Zuo
Journal:  J Cell Mol Med       Date:  2016-07-04       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.